Oppenheimer Maintains Their Buy Rating on Chinook Therapeutics (KDNY)


In a report released today, Justin Kim from Oppenheimer maintained a Buy rating on Chinook Therapeutics (KDNY), with a price target of $25.00. The company’s shares closed last Thursday at $15.43.

According to TipRanks.com, Kim is a 5-star analyst with an average return of 32.5% and a 65.5% success rate. Kim covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Apellis Pharmaceuticals, and Aldeyra Therapeutics.

Currently, the analyst consensus on Chinook Therapeutics is a Strong Buy with an average price target of $27.25, which is a 76.6% upside from current levels. In a report issued on October 12, William Blair also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KDNY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company’s platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts